Objective: To systematically evaluate the clinical effect of Kanglaite (KLT) injection-assisted gemcitabine plus cisplatin (GP) regimen on non-small cell lung cancer (NSCLC).
Methods: The CNKI, WanFang, VIP, Chinese Biomedical Database, PubMed, Embase and Cochrane Library databases were searched to collect the randomized controlled trials (RCTs), which evaluated the clinical effect of KLT combined with GP chemotherapy on NSCLC, published as of February 15, 2023. These articles were screened, extracted and evaluated. Revman 5.3 and STATA 17 were used for analysis, where the odds ratio (OR) was used as the statistic for the binary variables, and the mean difference (MD) was used as the statistic for the continuous variables.
Results: After selection, this meta-analysis included 27 RCTs and 2,579 patients. Comparing with GP chemotherapy, KLT combined with GP regimen enhanced the total response rate (=1.76, 95% : 1.49-2.06, <0.00001), improved the Karnofsky (KPS) score (=2.03, 95% : 1.55-2.66, <0.00001), decreased the adverse reactions, including gastrointestinal reactions (=0.41, 95% : 0.33-0.51, <0.00001), leucopenia (=0.45, 95% : 0.35-0.58, <0.00001), anemia (=0.47, 95% : 0.32-0.67, <0.0001) and liver function damage (=0.52, 95% : 0.38-0.73, <0.0001), as well as elevated immune level, including CD3 (=8.51, 95% : 7.63-9.39, <0.00001), CD4 (=5.68, 95% : 5.08-6.27, <0.00001) and CD4/CD8 (=0.41, 95% : 0.38-0.44, <0.00001).
Conclusions: Current evidence shows that the combination regimen of KLT with GP has shown promising results in increasing the response rate, improving the KPS score, enhancing the immune level, and reducing the incidence of adverse reactions in NSCLC patients. However, this conclusion needs to be further verified due to limitations such as the limited number of articles included in this paper and the variability in research methodology and quality among the included studies.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10250993 | PMC |
Publication Analysis
Top Keywords
Similar Publications
Kanglaite alleviates lung squamous cell carcinoma through ferroptosis.
Int Immunopharmacol
January 2025
Department of Neurology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu 611731, China. Electronic address:
Kanglaite, a compound predominantly composed of polyunsaturated fatty acids (PUFAs), has been employed in the clinical treatment of adenocarcinoma non-small cell lung cancer (NSCLC) in China for decades. However, its therapeutic efficacy and specific mechanism in the treatment of squamous NSCLC remains unexplored. In this study, we demonstrate that the co-treatment with ferric ion significantly enhances the cytotoxic effects of kanglaite by inducing ferroptosis in NCL-H1703, a cell line of human lung squamous cell carcinoma.
View Article and Find Full Text PDFSeven oral traditional Chinese medicine combined with chemotherapy for the treatment of non-small cell lung cancer: a network meta-analysis.
Pharm Biol
December 2024
Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Context: Traditional Chinese medicines (TCMs) have emerged as potential adjuvant therapies to treat non-small cell lung cancer. More direct comparative studies must be conducted among various oral TCMs.
Objective: This network meta-analysis evaluates the efficacy and safety of seven oral TCMs combined with chemotherapy in treating NSCLC.
Comparative efficacy and safety of Chinese medicine injections as an adjunctive therapy for cervical cancer in Chinese patients: a network meta-analysis.
Pharm Biol
December 2024
College of Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan, China.
Context: Chinese medicine injections (CMIs) are widely used as adjuvant therapy for cervical cancer in China. However, the effectiveness of different types of CMIs remains uncertain.
Objective: To assess the effectiveness and safety of CMIs when used in conjunction with radiotherapy (RT) or concurrent chemoradiotherapy (CCRT), particularly in combination with cisplatin (DDP), docetaxel plus cisplatin (DP), and paclitaxel plus cisplatin (TP).
Efficacy and safety of Chinese medicine injections in combination with docetaxel and cisplatin for non-small cell lung cancer: a network meta-analysis.
Front Pharmacol
December 2023
General Practice, Shenzhen Hospital of Integrated Traditional Chinese and Western Medicine, Shenzhen, Guangdong, China.
Non-small cell lung cancer (NSCLC) poses a serious threat to human health. Several clinical studies have reported the benefits of Chinese herbal injections (CHIs) in combination with docetaxel and cisplatin (DP). This multidimensional network meta-analysis aimed to investigate the preferred regimen of CHIs in combination with DP for the treatment of NSCLC.
View Article and Find Full Text PDFChinese herbal injections in combination with radiotherapy for advanced pancreatic cancer: A systematic review and network meta-analysis.
Integr Med Res
December 2023
Centre for Evidence-based Chinese Medicine, School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China.
Background: Advanced pancreatic cancer (APC) is a fatal disease with limited treatment options. This study aims to evaluate the effectiveness and safety of different Chinese herbal injections (CHIs) as adjuvants for radiotherapy (RT) in APC and compare their treatment potentials using network meta-analysis.
Methods: We systematically searched three English and four Chinese databases for randomized controlled trials (RCTs) from inception to July 25, 2023.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!